Skip to main content

Advertisement

SpringerLink
Log in

Neuroendocrine tumors of the lung: clinicopathological and molecular features

  • Review Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

In 1970, neuroendocrine tumors of the lung were classified into three categories: typical carcinoid (TC), atypical carcinoid (AC), and small cell lung carcinoma (SCLC). The third edition of the World Health Organization (WHO) classification in 1999 defined large cell neuroendocrine carcinoma (LCNEC) as a variant of large cell carcinomas, whereas the fourth edition of the WHO classification redefined LCNEC as a neuroendocrine tumor. Currently, neuroendocrine tumors of the lung are classified into four main categories: TC, AC, LCNEC, and SCLC. Although the treatments for TC, AC, and SCLC have not changed remarkably, the treatment strategy for LCNEC is not yet established because of its reclassification from a variant of “large cell carcinoma” to a new category of “neuroendocrine tumor”. In this review article, we discuss the pathological findings, biological behavior, and treatment of neuroendocrine tumors of the lung.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Iyoda A. Biological and clinicopathological features of pulmonary large-cell neuroendocrine carcinoma—a new era of research. Toho J Med. 2018;4:35–42.

    Google Scholar 

  2. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 1972;64:413–21.

    CAS  PubMed  Google Scholar 

  3. World Health Organization. Histological typing of lung and pleural tumours. 3rd ed. Germany: Springer; 1999.

    Google Scholar 

  4. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, editors. WHO classification of tumours of the lung, pleural, thymus and heart. 4th ed. Lyon: IARC; 2015.

    Google Scholar 

  5. Iyoda A, Hiroshima K, Baba M, Saitoh Y, Ohwada H, Fujisawa T. Pulmonary large cell carcinomas with neuroendocrine features are high grade neuroendocrine tumors. Ann Thorac Surg. 2002;73:1049–54.

    PubMed  Google Scholar 

  6. Soga J, Yakuwa Y. Bronchopulmonary carcinoids: an analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg. 1999;5:211–9.

    CAS  PubMed  Google Scholar 

  7. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. Am J Surg Pathol. 1991;15:529–53.

    CAS  PubMed  Google Scholar 

  8. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg. 1996;62:798–810.

    CAS  PubMed  Google Scholar 

  9. Onuki N, Wistuba II, Travis WD, Virmani AK, Yashima K, Brambilla E, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer. 1999;85:600–7.

    CAS  PubMed  Google Scholar 

  10. Walch AK, Zitzelsberger HF, Aubele MM, Mattis AE, Bauchinger M, Candidus S, et al. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Am J Pathol. 1998;153:1089–98.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001;119:1647–51.

    CAS  PubMed  Google Scholar 

  12. Rea F, Rizzardi G, Zuin A, Marulli G, Nicotra S, Bulf R, et al. Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. Eur J Cardiothorac Surg. 2007;31:186–91.

    PubMed  Google Scholar 

  13. Daddi N, Ferolla P, Urbani M, Semeraro A, Avenia N, Ribacchi R, et al. Surgical treatment of neuroendocrine tumors of the lung. Eur J Cardiothorac Surg. 2004;26:813–7.

    PubMed  Google Scholar 

  14. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934–44.

    CAS  PubMed  Google Scholar 

  15. Ferguson MK, Landreneau RJ, Hazelrigg SR, Altorki NK, Naunheim KS, Zwischenberger JB, et al. Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg. 2000;18:156–61.

    CAS  PubMed  Google Scholar 

  16. Fox M, Van Berkel V, Bousamra M 2nd, Sloan S, Martin RC 2nd. Surgical management of pulmonary carcinoid tumors: sublobar resection versus lobectomy. Am J Surg. 2013;205:200–8.

    PubMed  Google Scholar 

  17. Chen F, Sato T, Fujinaga T, Sakai H, Miyahara R, Bando T, et al. Surgical management of bronchopulmonary typical carcinoid tumors: an institutional experience. Interact Cardiovasc Thorac Surg. 2010;11:737–9.

    CAS  PubMed  Google Scholar 

  18. Costes V, Marty-Ané C, Picot MC, Serre I, Pujol JL, Mary H, et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study. Hum Pathol. 1995;26:740–5.

    CAS  PubMed  Google Scholar 

  19. National Comprehensive Cancer Network. Neuroendocrine and adrenal tumors. NCCN Guidelines, version 2.2018: NET-6-NET-9. NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/default.aspx.

  20. Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26:1604–20.

    CAS  PubMed  Google Scholar 

  21. Wolin EM. Advances in the diagnosis and management of well-differentiated and intermediate-differentiated neuroendocrine tumors of the lung. Chest. 2017;151:1141–6.

    PubMed  Google Scholar 

  22. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968–77.

    CAS  PubMed  Google Scholar 

  23. Tsuruoka K, Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, et al. PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer. 2017;108:115–20.

    PubMed  Google Scholar 

  24. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer. 2001;91:1992–2000.

    CAS  PubMed  Google Scholar 

  25. Iyoda A, Baba M, Hiroshima K, Saitoh H, Moriya Y, Shibuya K, et al. Imprint cytologic features of pulmonary large cell neuroendocrine carcinoma: comparison with classic large cell carcinoma. Oncol Rep. 2004;11:285–8.

    PubMed  Google Scholar 

  26. Nitadori J, Ishii G, Tsuta K, Yokose T, Murata Y, Kodama T, et al. Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. Am J Clin Pathol. 2006;125:682–92.

    PubMed  Google Scholar 

  27. Iyoda A, Hiroshima K, Moriya Y, Mizobuchi T, Otsuji M, Sekine Y, et al. Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. Ann Thorac Surg. 2004;77:1891–5.

    PubMed  Google Scholar 

  28. Jiang SX, Kameya T, Sato Y, Yanase N, Yoshimura H, Kodama T. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol. 1996;148:837–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Arbiser ZK, Arbiser JL, Cohen C, Gal AA. Neuroendocrine lung tumors: grade correlates with proliferation but not angiogenesis. Mod Pathol. 2001;14:1195–9.

    CAS  PubMed  Google Scholar 

  30. Przygodzki RM, Finkelstein SD, Langer JC. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol. 1996;148:1531–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Gugger M, Burckhardt E, Kappeler A, Hirsiger H, Laissue JA, Mazzucchelli L. Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas. J Pathol. 2002;196:408–15.

    CAS  PubMed  Google Scholar 

  32. Zaffaroni N, De Polo D, Villa R, Della Porta C, Collini P, Fabbri A, et al. Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping. J Pathol. 2003;201:127–33.

    CAS  PubMed  Google Scholar 

  33. Ullmann R, Petzmann S, Sharma A, Cagle PT, Popper HH. Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum Pathol. 2001;32:1059–63.

    CAS  PubMed  Google Scholar 

  34. Peng WX, Shibata T, Katoh H, Kokubu A, Matsuno Y, Asamura H, et al. Array-based comparative genomic hybridization analysis of high-grade neuroendocrine tumors of the lung. Cancer Sci. 2005;96:661–7.

    CAS  PubMed  Google Scholar 

  35. Hiroshima K, Iyoda A, Shida T, Shibuya K, Iizasa T, Kishi H, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol. 2006;19:1358–68.

    CAS  PubMed  Google Scholar 

  36. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet. 2004;363:775–81.

    CAS  PubMed  Google Scholar 

  37. Hiroshima K, Iyoda A, Shibuya K, Haga Y, Toyozaki T, Iizasa T, et al. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. Cancer. 2004;100:1190–8.

    CAS  PubMed  Google Scholar 

  38. Shin JH, Kang SM, Kim YS, Shin DH, Chang J, Kim SK, et al. Identification of tumor suppressor loci on the long arm of chromosome 5 in pulmonary large cell neuroendocrine carcinoma. Chest. 2005;128:2999–3003.

    CAS  PubMed  Google Scholar 

  39. Iyoda A, Jiang SX, Travis WD, Kurouzu N, Ogawa F, Amano H, et al. Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma. Mol Clin Oncol. 2013;1:437–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Igawa S, Watanabe R, Ito I, Murakami H, Takahashi T, Nakamura Y, et al. Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer. 2010;68:438–45.

    PubMed  Google Scholar 

  41. Tokito T, Kenmotsu H, Watanabe R, Ito I, Shukuya T, Ono A, et al. Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens. Int J Clin Oncol. 2014;19:63–7.

    CAS  PubMed  Google Scholar 

  42. Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer. 2012;77:365–70.

    PubMed  Google Scholar 

  43. Shimada Y, Niho S, Ishii G, Hishida T, Yoshida J, Nishimura M, et al. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens. Lung Cancer. 2012;75:368–73.

    PubMed  Google Scholar 

  44. Yamazaki S, Sekine I, Matsuno Y, Takei H, Yamamoto N, Kunitoh H, et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer. 2005;49:217–23.

    PubMed  Google Scholar 

  45. Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol. 2015;10:1133–41.

    PubMed  PubMed Central  Google Scholar 

  46. Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2015;33:3488–515.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Le Treut J, Sault MC, Lena H, Souquet PJ, Vergnenegre A, Le Caer H, et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013;24:1548–52.

    PubMed  Google Scholar 

  48. Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol. 2013;8:980–4.

    CAS  PubMed  Google Scholar 

  49. Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T. Pulmonary large cell neuroendocrine carcinoma—its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg. 2007;84:702–7.

    PubMed  Google Scholar 

  50. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24:70–6.

    PubMed  Google Scholar 

  51. Iyoda A, Makino T, Koezuka S, Otsuka H, Hata Y. Treatment options for patients with large cell neuroendocrine carcinoma of the lung. Gen Thorac Cardiovasc Surg. 2014;62:351–6.

    PubMed  PubMed Central  Google Scholar 

  52. Iyoda A, Hiroshima K, Moriya Y, Sekine Y, Shibuya K, Iizasa T, et al. Prognostic impact of large cell neuroendocrine histology in patients with pathological stage 1a pulmonary non-small cell carcinoma. J Thorac Cardiovasc Surg. 2006;132:312–5.

    PubMed  Google Scholar 

  53. Takei H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg. 2002;124:285–92.

    PubMed  Google Scholar 

  54. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Baba M, Fujisawa T, et al. Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. Cancer. 2001;92:1108–12.

    CAS  PubMed  Google Scholar 

  55. Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2005;23:8774–855.

    CAS  PubMed  Google Scholar 

  56. Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 2006;82:1802–7.

    PubMed  Google Scholar 

  57. Veronesi G, Morandi U, Alloisio M, Terzi A, Cardillo G, Filosso P, et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer. 2006;53:111–5.

    PubMed  Google Scholar 

  58. Iyoda A, Hiroshima K, Moriya Y, Iwadate Y, Takiguchi Y, Uno T, et al. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg. 2009;138:446–53.

    PubMed  Google Scholar 

  59. Saji H, Tsuboi M, Matsubayashi J, Miyajima K, Shimada Y, Imai K, et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs. 2010;21:89–93.

    CAS  PubMed  Google Scholar 

  60. Sarkaria IS, Iyoda A, Roh MS, Sica G, Kuk D, Sima CS, et al. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. Ann Thorac Surg. 2011;92:1180–6.

    PubMed  Google Scholar 

  61. Filosso PL, Guerrera F, Evangelista A, Galassi C, Welter S, Rendina EA, ESTS Lung Neuroendocrine Working Group Contributors, et al. Adjuvant chemotherapy for large-cell neuroendocrine lung carcinoma: results from the European Society for Thoracic Surgeons Lung Neuroendocrine Tumours retrospective database. Eur J Cardiothorac Surg. 2017;52:339–45.

    PubMed  Google Scholar 

  62. Kim KW, Kim HK, Kim J, Shim YM, Ahn MJ, Choi YL. Outcomes of curative-intent surgery and adjuvant treatment for pulmonary large cell neuroendocrine carcinoma. World J Surg. 2017;41:1820–7.

    PubMed  Google Scholar 

  63. Wakeam E, Adibfar A, Stokes S, Leighl NB, Giuliani ME, Varghese TK Jr, et al. Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg. 2019. https://doi.org/10.1016/j.jtcvs.2019.09.077.

    Article  PubMed  Google Scholar 

  64. Dresler CM, Ritter JH, Patterson GA, Ross E, Bailey MS, Wick MR. Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg. 1997;63:180–5.

    CAS  PubMed  Google Scholar 

  65. Iyoda A, Travis WD, Sarkaria IS, Jiang SX, Amano H, Sato Y, et al. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. Exp Ther Med. 2011;2:1041–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. De Pas TM, Giovannini M, Manzotti M, Trifirò G, Toffalorio F, Catania C, et al. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J Clin Oncol. 2011;29:e819–e822822.

    PubMed  Google Scholar 

  67. Yanagisawa S, Morikawa N, Kimura Y, Nagano Y, Murakami K, Tabata T. Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma. Respirology. 2012;17:1275–7.

    PubMed  Google Scholar 

  68. Sakai Y, Yamasaki T, Kusakabe Y, Kasai D, Kotani Y, Nishimura Y, et al. Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature. Multidiscip Respir Med. 2013;8:47.

    PubMed  PubMed Central  Google Scholar 

  69. Yoshida Y, Ota S, Murakawa T, Takai D, Nakajima J. Combined large cell neuroendocrine carcinoma and adenocarcinoma with epidermal growth factor receptor mutation in a female patient who never smoked. Ann Thorac Cardiovasc Surg. 2014;20(Suppl):582–4.

    PubMed  Google Scholar 

  70. Makino T, Mikami T, Hata Y, Otsuka H, Koezuka S, Isobe K, et al. Comprehensive biomarkers for personalized treatment in pulmonary large cell neuroendocrine carcinoma: a comparative analysis with adenocarcinoma. Ann Thorac Surg. 2016;102:1694–701.

    PubMed  Google Scholar 

  71. Christopoulos P, Engel-Riedel W, Grohé C, Kropf-Sanchen C, von Pawel J, Gütz S, et al. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. Ann Oncol. 2017;28:1898–902.

    CAS  PubMed  Google Scholar 

  72. Miyoshi T, Umemura S, Matsumura Y, Mimaki S, Tada S, Makinoshima H, et al. Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin Cancer Res. 2017;23:757–65.

    CAS  PubMed  Google Scholar 

  73. Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, et al. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer. 2017;5:75.

    PubMed  PubMed Central  Google Scholar 

  74. Odate S, Nakamura K, Onishi H, Kojima M, Uchiyama A, Nakano K, et al. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer. 2013;79:205–14.

    PubMed  Google Scholar 

  75. Araki K, Ishii G, Yokose T, Nagai K, Funai K, Kodama K, et al. Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer. 2003;40:173–80.

    PubMed  Google Scholar 

  76. Casali C, Stefani A, Rossi G, Migaldi M, Bettelli S, Parise A, et al. The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg. 2004;77:247–53.

    PubMed  Google Scholar 

  77. Pelosi G, Masullo M, Leon ME, Veronesi G, Spaggiari L, Pasini F, et al. CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. Virchows Arch. 2004;445:449–55.

    PubMed  Google Scholar 

  78. Yokouchi H, Kitahashi M, Oshitari T, Yamamoto S. Intravitreal bevacizumab for iris tumor metastasized from large cell neuroendocrine carcinoma of lung. Graefes Arch Clin Exp Ophthalmol. 2013;251:2243–5.

    PubMed  Google Scholar 

  79. Derks JL, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, Groen HJM, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24:33–42.

    CAS  PubMed  Google Scholar 

  80. Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res. 2016;22:3618–29.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Rekhtman N, Pietanza CM, Sabari J, Montecalvo J, Wang H, Habeeb O, et al. Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. Mod Pathol. 2018;31:111–21.

    CAS  PubMed  Google Scholar 

  82. Tanaka Y, Ogawa H, Uchino K, Ohbayashi C, Maniwa Y, Nishio W, et al. Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma: a possible association between staining patterns with neuroendocrine markers and tumor response to chemotherapy. J Thorac Cardiovasc Surg. 2013;145:839–46.

    CAS  PubMed  Google Scholar 

  83. Minami K, Tanaka Y, Ogawa H, Jimbo N, Nishio W, Yoshimura M, Itoh T, Maniwa Y. Neuroendocrine marker staining pattern categorization of small-sized pulmonary large cell neuroendocrine carcinoma. Thorac Cancer. 2019;10:2152–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Kusafuka K, Ferlito A, Lewis JS Jr, Woolgar JA, Rinaldo A, Slootweg PJ, et al. Large cell neuroendocrine carcinoma of the head and neck. Oral Oncol. 2012;48:211–5.

    PubMed  Google Scholar 

  85. Ose N, Inoue M, Morii E, Shintani Y, Sawabata N, Okumura M. Multimodality therapy for large cell neuroendocrine carcinoma of the thymus. Ann Thorac Surg. 2013;96:e85–e8787.

    PubMed  Google Scholar 

  86. Embry JR, Kelly MG, Post MD, Spillman MA. Large cell neuroendocrine carcinoma of the cervix: prognostic factors and survival advantage with platinum chemotherapy. Gynecol Oncol. 2011;120:444–8.

    PubMed  Google Scholar 

  87. Yoseph B, Chi M, Truskinovsky AM, Dudek AZ. Large-cell neuroendocrine carcinoma of the cervix. Rare Tumors. 2012;4:e18.

    PubMed  PubMed Central  Google Scholar 

  88. Oberstein PE, Kenney B, Krishnamoorthy SK, Woo Y, Saif MW. Metastatic gastric large cell neuroendocrine carcinoma: a case report and review of literature. Clin Colorectal Cancer. 2012;11:218–23.

    PubMed  Google Scholar 

  89. Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006;30:684–93.

    PubMed  Google Scholar 

  90. Shimono C, Suwa K, Sato M, Shirai S, Yamada K, Nakamura Y, et al. Large cell neuroendocrine carcinoma of the gallbladder: long survival achieved by multimodal treatment. Int J Clin Oncol. 2009;14:351–5.

    PubMed  Google Scholar 

  91. National Comprehensive Cancer Network. Small cell lung cancer. NCCN guidelines, version 2.2018. NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/default.aspx.

  92. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med. 2002;346:85–91.

    CAS  PubMed  Google Scholar 

  93. Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, Zhan Q. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol. 2010;5:867–73.

    PubMed  Google Scholar 

  94. Lima JP, dos Santos LV, Sasse EC, Lima CS, Sasse AD. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. J Thorac Oncol. 2010;5:1986–93.

    PubMed  Google Scholar 

  95. Horn L, Mansfield AS, Szczsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9.

    CAS  PubMed  Google Scholar 

  96. Varghese AM, Zakowski MF, Yu HA, Won HH, Riely GJ, Krug LM, et al. Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol. 2014;9:892–6.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

We received no funding for this manuscript.

Author information

Authors and Affiliations

  1. Division of Chest Surgery, Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan

    Akira Iyoda, Yoko Azuma & Atsushi Sano

Authors
  1. Akira Iyoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoko Azuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Atsushi Sano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akira Iyoda.

Ethics declarations

Conflict of interest

We have no conflict of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iyoda, A., Azuma, Y. & Sano, A. Neuroendocrine tumors of the lung: clinicopathological and molecular features. Surg Today 50, 1578–1584 (2020). https://doi.org/10.1007/s00595-020-01988-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-020-01988-7

Keywords

Search

Navigation